Abstract: The present disclosure relates to a process for producing levulinic acid from the technical lignin. The technical lignin is rich in lignin and ash and do not have any other use and usually incinerated as a waste management strategy. During the incineration process, the cellulose also gets burnt and wasted.

Abstract: Disclosed are various embodiments for providing content to virtual machines. A request for content can be received, wherein the request originates from a virtual machine hosted by the computing device, comprises a unique identifier for the content, and is received from the virtual machine through an inter-process communication mechanism. The unique identifier can be validated. Content can then be retrieved using the unique identifier. A copy of the content can then be provided to the virtual machine in response to validation of the unique identifier, the content being provided to the virtual machine through the inter-process communication mechanism.

Abstract: The present invention relates to a method based on proton NMR technique to differentiate genuine and spurious Hand-rub formulations. This method identifies and estimates all four components present in WHO-recommended Hand-rub formulations. Further, this method also identifies the presence of non-recommended/additional components present in WHO-recommended Hand-rub formulations. The method described in this invention utilizes experimental parameters and derived equations to quantify all four components in just fifteen minutes without using any organic solvents.

Abstract: In some aspects, the disclosure relates to BMP antagonists, such as BMP 10 propeptides, and methods of using BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: A thin-walled honeycomb body (100) having a plurality of repeating cell structures (110) formed of intersecting porous thick walls (112V, 112H) and thin walls (114V, 114H). Each repeating cell structure (110) is bounded on its periphery by the thick walls (112V, 122H) of a first transverse thickness (Tk) and the thin walls (114V, 114H) have a second transverse thickness (Tt) that subdivides each repeating cell structure (110) into between 7 and 36 individual cells (108). In the thin-walled honeycomb body (100), the first transverse thickness (Tk) of the thick walls (112V, 112H) is less than or equal to 0.127 mm (0.005 inch) and the second transverse thickness (Tt) of the thin walls (114V, 114H) is less than or equal to 0.0635 mm (0.0025 inch), and Tk>Tt. Honeycomb extrusion dies and methods of manufacturing the thin-walled honeycomb body (100) having thick walls (112V, 112H) and thin walls (114V, 114H) are provided.

Abstract: In certain aspects, the disclosure provides soluble heteromeric polypeptide complexes comprising an extracellular domain of a type I serine/threonine kinase receptor of the TGF-beta family and an extracellular domain of a type II serine/threonine kinase receptor of the TGF-beta family. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type II receptor selected from: ActRIIA, ActRIIB, TGFBRII, BMPRII, and MISRII. In some embodiments, the disclosure provides soluble polypeptide complexes comprising an extracellular domain of a type I receptor selected from: ALK1, ALK2, ALK3, ALK4, ALK5, ALK6, and ALK7. Optionally the soluble complex is a heterodimer. In certain aspects, such soluble polypeptide complexes may be used to regulate (promote or inhibit) growth of tissues or cells including, for example, muscle, bone, cartilage, fat, neural tissue, tumors, cancerous cells, and/or cells of hematopoietic lineages, including red blood cells.

Abstract: An electronic device may have a plurality of defined life cycle stages and a one-time-programmable (OTP) memory comprising a plurality of life cycle bits, wherein respective bit patterns of the life cycle bits may correspond with respective life cycle stages of the defined life cycle stages. The electronic device may also have a boot code stored in read only memory and executable by a processor to receive a request to transition from a current life cycle stage to a next life cycle stage and, in response to the received request, automatically generate a bit pattern corresponding to the next life cycle stage of the plurality of defined life cycle stages and program the bit pattern corresponding to the next life cycle stage of the plurality of defined life cycle stages in the OTP memory during a time when the OTP memory is not user-accessible.

Abstract: An electronic device includes a transaction host, first and second peripherals, memory, an access control register, and first and second access controllers. The memory stores access control identifier management instructions, a first task related to the first peripheral, and a first bitmask indicating respective access settings for the first and second peripherals for performing the first task. The access control register includes a first access control identifier for the first peripheral and a second access control identifier for the second peripheral. The transaction host executes the access control identifier management instructions to program the first and second access control identifiers based on the first bitmask, and subsequently executes the first task. The first and second access controllers control access to the first and second peripherals, respectively, based on the respective first and second access control identifiers programmed based on the first bitmask.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: This disclosure provides ALK7-binding proteins such as anti-ALK7 antibodies, and compositions and methods for making the ALK7-binding proteins. In certain embodiments the ALK7-binding proteins inhibit, or antagonize ALK7 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating overweight, obesity, diabetes, overweight, obesity, type 2 diabetes, and their associated conditions; metabolic disorders, and other diseases or conditions that can be treated, prevented or ameliorated by targeting ALK7.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of pulmonary arterial hypertension, particularly treating, preventing or reducing the progression rate and/or severity of one or more pulmonary arterial hypertension associated complications.

Abstract: In some aspects, the disclosure relates to single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using single-arm ActRIIA heteromultimers and single-arm ActRIIB heteromultimers to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: In certain aspects, the present invention provides novel ActRIIB variants (in a homomultimeric or heteromultimeric form), as well as compositions and methods for using those variants to treat an indication associated with undesired activity of one or more TGF?-superfamily ligands. The present invention also provides methods of screening compounds that modulate activity of an ActRIIB protein and/or an ActRIIB ligand. The compositions and methods provided herein are useful in treating diseases associated with abnormal activity of an ActRIIB protein and/or an ActRIIB ligand.

Abstract: In some aspects, the disclosure relates to compositions and methods comprising ActRII polypeptides to treat, prevent, or reduce the progression rate and/or severity of post-capillary pulmonary hypertension (PcPH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PcPH-associated complications.

Abstract: A system for controlling viewing of multimedia is provided. The system includes an image capturing module captures images or videos of a user while viewing the multimedia. A mouth gesture identification module extracts facial features from the images captured of the user; identifies mouth gestures of the user based on the facial features extracted. A training module analyses the mouth gestures identified to determine parameters; builds a personalised support model for the user based on the parameters determined.

Abstract: Methods and apparatuses for improve data clock to reduce power consumption are presented. The apparatus includes a memory configured to receive a data clock from a host via a link and to synchronize the data clock with the host. The memory includes a clock tree buffer configured to toggle based on the data clock to capture write data or to output read data and a command decoder configured to detect a data clock suspend command while the data clock is synchronized between the host and the memory. The clock tree buffer is configured to disable toggling based on the data clock in response to the command decoder detecting the data clock suspend command. the host includes a memory controller configured to provide a data clock suspend command to the memory via the link while the data clock is synchronized between the host and the memory.

Abstract: In certain aspects, the present invention provides compositions and methods for increasing red blood cell and/or hemoglobin levels in vertebrates, including rodents and primates, and particularly in humans.

Abstract: In some aspects, the disclosure relates to single-arm AetRIIA heteromultimers and sing-arm ActRIIB heteromultimers and methods of using such heteromultimers to treat, prevent, or reduce tire progression rate and/or severity of renal diseases or conditions, particularly treating, preventing or reducing the progression rate and/or severity of one or more renal-associated complications. The disclosure also provides methods of using a single-arm ActRIIA heteromultimer or single-arm ActRIIB heteromultimer to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, Alport syndrome, focal segmental glomerulosclerosis (FSGS), polycystic kidney disease, and/or chronic kidney disease.

Abstract: In some aspects, the disclosure relates to ActRII antagonists and methods of using ActRII antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using an ActRII antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using an ActRII antagonist to reduce right ventricular systolic pressure in a subject in need thereof.

Abstract: In some aspects, the disclosure relates to GDF/BMP antagonists and methods of using GDF/BMP antagonists to treat, prevent, or reduce the progression rate and/or severity of pulmonary hypertension (PH), particularly treating, preventing or reducing the progression rate and/or severity of one or more PH-associated complications. The disclosure also provides methods of using a GDF/BMP antagonist to treat, prevent, or reduce the progression rate and/or severity of a variety of conditions including, but not limited to, pulmonary vascular remodeling, pulmonary fibrosis, and right ventricular hypertrophy. The disclosure further provides methods of using a GDF/BMP antagonist to reduce right ventricular systolic pressure in a subject in need thereof.